Which attention-deficit/hyperactivity disorder (ADHD) medications are approved for children aged 6 years and older?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ADHD Medications Approved for Age 6 and Older

For children aged 6 years and older with ADHD, FDA-approved medications include both stimulants (methylphenidate and amphetamine formulations in various short-acting, intermediate-acting, and long-acting preparations) and nonstimulants (atomoxetine, extended-release guanfacine, and extended-release clonidine). 1

Stimulant Medications (First-Line)

Stimulants remain the primary pharmacological treatment for children aged 6-17 years with ADHD:

Methylphenidate-Based Options

  • Short-acting formulations (immediate-release)
  • Intermediate-acting formulations
  • Long-acting formulations (extended-release)
  • Dexmethylphenidate (the active D-isomer of methylphenidate) in extended-release formulation 2
  • Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) - approved for patients ≥6 years 3

Amphetamine-Based Options

  • Short-acting amphetamine formulations
  • Long-acting amphetamine formulations
  • Mixed amphetamine salts extended-release (MAS-XR)
  • Lisdexamfetamine dimesylate (LDX) - a prodrug with reduced abuse potential 2

Nonstimulant Medications (Alternative or Adjunctive)

When stimulants are not tolerated, ineffective, or contraindicated, nonstimulant options are FDA-approved for children ≥6 years:

Primary Nonstimulants

  • Atomoxetine (Strattera) - norepinephrine reuptake inhibitor 4, 1
  • Extended-release guanfacine (Intuniv) - alpha-2 agonist 4, 1
  • Extended-release clonidine (Kapvay) - alpha-2 agonist 4, 1

Important distinction: Only extended-release guanfacine and extended-release clonidine have FDA approval for use as adjunctive therapy with stimulants. 4

Critical Clinical Considerations

Cardiovascular Monitoring

Before initiating any ADHD medication in children ≥6 years:

  • Obtain personal and family cardiac history
  • For nonstimulants specifically: perform ECG if risk factors present, consider cardiology referral if ECG abnormal 4
  • Atomoxetine increases heart rate and blood pressure
  • Guanfacine and clonidine decrease heart rate and blood pressure 4

Key Safety Warnings

Atomoxetine-specific concerns:

  • FDA black box warning for increased suicidal thoughts
  • Risk of hepatitis (extremely rare)
  • Initial somnolence and GI symptoms if dose escalated too rapidly
  • Growth delays in first 1-2 years (returns to expected trajectory by 2-3 years) 4

Alpha-agonist concerns (guanfacine/clonidine):

  • Must taper off gradually - never abruptly discontinue due to rebound hypertension risk 4
  • Common side effects: somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, abdominal pain 4

Treatment Selection Algorithm

  1. First-line: Stimulants (methylphenidate or amphetamine formulations) for children ≥6 years
  2. Second-line alternatives when stimulants fail or are contraindicated:
    • Atomoxetine as monotherapy
    • Extended-release guanfacine as monotherapy
    • Extended-release clonidine as monotherapy
  3. Adjunctive therapy: Add extended-release guanfacine OR extended-release clonidine to existing stimulant if partial response 4

Common Pitfalls to Avoid

  • Do not use immediate-release clonidine or guanfacine - only extended-release formulations have FDA approval for ADHD 1
  • Do not abruptly stop alpha-agonists - always taper to prevent rebound hypertension 4
  • Monitor for diversion risk in adolescents with stimulants - consider nonstimulants if high concern 4
  • Atomoxetine has slower onset compared to stimulants - may take several weeks for full effect 5

The 2019 AAP guidelines emphasize that for children aged 6 years and older, medication selection should prioritize efficacy while considering individual patient factors including comorbidities, side effect profile, abuse potential, and family preferences. 4, 6

References

Related Questions

What is the most effective stimulant for treating hyperactivity (attention‑deficit/hyperactivity disorder)?
Which stimulant medication is best for treating ADHD?
What are the newest FDA‑approved medications for attention‑deficit/hyperactivity disorder, what level of evidence supports them, and what are the recommended dosing and usage guidelines?
Which stimulant medication should be initiated for a 7-year-old male newly diagnosed with attention-deficit/hyperactivity disorder?
What medication options are available for treating ADHD in a 12‑year‑old child?
In an asymptomatic individual with a urinalysis showing leukocyte esterase 2+, bacteria 1+, 16‑30 white blood cells per high‑power field, and 16‑30 epithelial cells per high‑power field, what is the appropriate next step in management?
What are the recommended omeprazole dosing regimens and treatment durations for gastro‑oesophageal reflux disease (GERD), duodenal or gastric ulcer healing, Helicobacter pylori eradication, and Zollinger‑Ellison syndrome?
What is the appropriate next diagnostic step for a 37‑year‑old woman with painful, rapidly enlarging lumbar subcutaneous nodules (≈1 cm and 4 cm), not visible on the skin but palpable, and associated idiopathic urticaria, chronic lymphadenopathy, fatigue, and steroid‑responsive pain?
What is the best treatment approach for a senior female with a chronic complete supraspinatus tendon tear?
Are steroids used in the treatment of Hashimoto's thyroiditis?
In an 89-year-old patient with sudden left-sided rib pain and a CT scan that has excluded renal stones, diverticulitis, and other intra-abdominal pathology, what is the appropriate immediate evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.